Magnesium Sulfate for Fetal Neuroprotection

Launched by CAIRO UNIVERSITY · May 22, 2020

Keywords

ClinConnect Summary

Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological changes according to NICE guidelines 2017) in any of the groups will receive the allocated treatment at least 20 minute before the procedure (emergency CS).

measures to reduce the effect of hypoxia will be applied to all participate through:

* The position of the mother will be changed to left lateral position (allow increased blood supply).
* I.V. fluid bolus (to avoid maternal dehydration).
* Oxytocin or cervical ripening agent will be discontinued.
* Fetal heart rate monitoring with cardiotocogr...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women at least 37 week of gestation.
• • Not more than 35 years old.
• • Fetal distress (perinatal asphyxia) diagnosed by CTG changes (Non reassuring or pathological changes according to NICE guidelines 2017).
• • Clinical chorioamnionitis.
• • Prolonged rupture of membranes
• Exclusion Criteria:
• • Medical disorders such as chronic hypertension, preeclampsia, eclampsia, DM, pulmonary hypertension, hepatic coma with risk of renal failure, and any renal, cardiac or pulmonary disease.
• • RH -ve.
• • Consanguinity.
• • Preterm labor.
• • Fetal malpresentation.
• • Contraindications to the use of Magnesium Sulphate.
• • Any indication for magnesium Sulphate therapy (seizure prophylaxis or tocolysis).
• • Myasthenia gravis.
• • Congenital fetal anomalies.
• • Fetal growth restriction (birth weight \< 10th Percentile for gestational age).
• • Advanced cervical dilation (8cm).